However, our study found the tumor stage was more advanced in the population with high-risk group and more CD4+ T cells, and this group had better efficacy with drugs such as sorafenib and higher expression of PD-1 and CTLA-4, suggesting that the group may have a better outcome with combination therapy despite their late staging. The gene discussed is CTLA4; the disease is neoplasm.